Horizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant Program
Horizon Therapeutics (NASDAQ: HZNP) has opened applications for its 2023 #RAREis Global Advocate Grant, which offers 50 advocacy groups a one-time grant of
- Expanded grant program offering $5,000 to 50 advocacy groups.
- Increased number of grants offered from 30 to 50, showcasing commitment to support.
- Focused on addressing critical needs of the rare disease community.
- None.
-- In 2023, 50 global patient advocacy groups will be eligible to receive a one-time,
-- Livestream with #RAREis Global Advocate Grant recipients discussing global challenges in rare disease to be held on
The #RAREis Global Advocate Grant expands communication and awareness for the rare disease community by providing financial assistance to patient advocacy groups working to advance, educate and address challenges faced by rare disease families. The program aims to build equity for the rare disease community by empowering and fostering growth for small, often overlooked advocacy organizations around the world.
With an estimated 400 million people worldwide living with a rare disease, the need for support and funding is critical to advance educational programs, research and improving care. Horizon launched the program in 2022 and received more than 120 applications, from 12 countries, spanning nearly 100 different rare diseases.
The 30 organizations awarded the 2022 #RAREis Global Advocate Grant represented 29 unique rare diseases and represented nine countries, including diseases so uncommon they do not have a name but are categorized by genetic variant. Grant recipients used funding to establish new programs, develop educational resources and expand their current offerings to support their disease communities.
“Addressing problems in rare disease can mean the difference in saving a life – the families we serve are facing clinicians and a healthcare system that often refuse their care because the disease is deemed incompatible with life,” said
This year, advocacy groups will be eligible to receive a one-time,
“Rare disease advocacy is often driven at the local level, propelled by families and people touched by a rare disorder, passionate about finding a cure and providing support for their loved ones,” said
Horizon will be hosting a global conversation, “#RAREis Global Advocate Grant: Addressing Issues in the
About #RAREis
In February of 2017, Horizon launched the #RAREis program aimed at elevating the voices, faces and experiences of people living with rare diseases, as well as highlight programs and resources for the rare disease community. The program is anchored by an Instagram page and website that showcases photos and stories of people touched by rare disease and captures elements of their patient, caregiver or advocate experience. To learn more, visit the #RAREis Instagram and Facebook page and visit the website at www.RAREisCommunity.com.
About Horizon
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005315/en/
Senior Manager, Communications
media@horizontherapeutics.com
Ireland Media:
Gordon MRM
ray@gordonmrm.ie
Source:
FAQ
What is the #RAREis Global Advocate Grant offered by Horizon Therapeutics?
When can organizations apply for the #RAREis Global Advocate Grant?
How many grants were awarded in 2022 under the #RAREis program?
What is the purpose of the #RAREis grant?